CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income (loss)	$ 2,408,000	$ 214,000
Adjustments to reconcile net income (loss) to net cash:
Stock compensation expense	343,000	592,000
Foreign exchange loss (gain)	11,000	164,000
Depreciation and amortization	926,000	939,000
Deferred income taxes	(2,775,000)	29,000
Non-cash R&D services	238,000	0
Other	68,000	131,000
Other changes in assets and liabilities:
Accounts receivable, net	74,000	(1,760,000)
Inventories	(408,000)	(1,090,000)
Costs in excess of billings and unbilled receivables	25,000	268,000
Prepaid expenses and other assets	188,000	(92,000)
Accounts payable	(197,000)	(74,000)
Accrued expenses and other liabilities	(480,000)	157,000
Deferred revenue	(129,000)	119,000
Net cash from operating activities	292,000	(403,000)
Cash flows from investing activities:
Purchases of property, plant and equipment	(455,000)	(1,267,000)
Purchase of intangibles	(78,000)	(75,000)
Net cash from investing activities	(533,000)	(1,342,000)
Cash flows from financing activities:
Proceeds from issuance of common stock	13,000	11,000
Net proceeds from issuance of convertible notes	0	390,000
Principal payments on capital leases	(80,000)	(101,000)
Proceeds from (payments of) line of credit, net	0	649,000
Proceeds from (payments of) bank and subordinated debt, net	(490,000)	(186,000)
Net cash from financing activities	(557,000)	763,000
Effect of exchange rates on cash and cash equivalents	(19,000)	(81,000)
Net change in cash and cash equivalents	(817,000)	(1,063,000)
Cash and cash equivalents, beginning	2,607,000	1,295,000
Cash and cash equivalents, ending	1,790,000	232,000
Non cash activities:
Assets purchased under capital leases	0	240,000
Tax payments (refunds)	0	(64,000)
Recapitalization of Xcede - conversion of non controlling notes payable to preferred stock	(3,103,000)	0
Subsidiary stock options issued to settle liabilities	75,000	0
Subsidiary debt issued to fund research activities	$ 500,000	$ 0